Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

64 Suchergebnisse.
Relevanz Bewertung Neue zuerst Alte zuerst

Eligibility SWAP Acute Coronary Syndrome NCT00356135 - Eligibility Criteria

- 28.07.15 - 1 Formular, 2 Itemgruppen, 18 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
This study will compare the effect of a prasugrel 10-mg maintenance dose with a clopidogrel 75-mg maintenance dose on platelet activity, approximately 1 week after the first dose of study drug, in subjects who have been taking clopidogrel 75 mg daily following a percutaneous coronary intervention (PCI) with placement of a stent, performed to treat acute coronary syndrome (ACS). https://clinicaltrials.gov/ct2/show/NCT00356135

Eligibility Dalteparin Acute Coronary Syndrome NCT00922766 - Eligibility Criteria

- 28.07.15 - 1 Formular, 2 Itemgruppen, 8 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
To collect data on safety and effectiveness of dalteparin in the management of non-ST segment elevated acute coronary syndromes in nursing home patients who will be treated conservatively (without percutaneous corornary intervention [PCI] or coronary artery bypass graft [CABG] within 48 hours). https://clinicaltrials.gov/ct2/show/NCT00922766

Eligibility EARLY ACS Acute Coronary Syndrome NCT00089895 - Eligibility criteria

- 28.07.15 - 1 Formular, 2 Itemgruppen, 16 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion criteria
The purpose of this study is to see if early INTEGRILIN® (eptifibatide) therapy in patients with non-ST-segment elevation acute coronary syndrome (ACS) reduces the occurence of death, heart attack and urgent cardiac intervention (surgery) compared to placebo (with delayed provisional use of eptifibatide). https://clinicaltrials.gov/ct2/show/NCT00089895

Eligibility ROMICAT-II Acute Coronary Syndrome NCT01084239 - Eligibility Critera

- 28.07.15 - 1 Formular, 2 Itemgruppen, 35 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
The growing availability of cardiac computed tomography (CT)* in emergency departments (EDs) across the U.S. expands the opportunities for its clinical application, but also heightens the need to define its appropriate use in the evaluation of patients with acute chest pain. To address this need, we performed a randomized diagnostic trial (RDT) to determine whether integrating cardiac CT, along with the information it provides on coronary artery disease (CAD) and left ventricular (LV) function, can improve the efficiency of the management of these patients (i.e. shorten length of hospital stay, increase direct discharge rates from the ED, decreasing healthcare costs and improving cost effectiveness while being safe). https://clinicaltrials.gov/ct2/show/NCT01084239

Eligibility PLATO Acute Coronary Syndrome NCT00391872 - Eligibility Criteria

- 28.07.15 - 1 Formular, 2 Itemgruppen, 7 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots. Ticagrelor is being developed as a treatment for patients with acute coronary syndrome (ACS). ACS is a term that is used to describe both heart attacks in progress or the imminent threat of a heart attack. ACS is usually caused by the formation of a blood clot in an artery that partially or totally blocks the blood supply to a portion of the heart muscle. Ticagrelor will be compared with clopidogrel to determine which drug, when either is used in conjunction with aspirin, is better at reducing deaths from vascular causes, future heart attacks and/or strokes in patients with ACS. https://clinicaltrials.gov/ct2/show/NCT00391872

Eligibility FUTURA/OASIS 8 Acute Coronary Syndrome NCT00790907 - Eligibility Criteria

- 28.07.15 - 1 Formular, 2 Itemgruppen, 32 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
The purpose of this study is to compare the safety of two different dose regimens of unfractionated heparin (UFH) during a percutaneous coronary intervention (PCI) procedure in patients with UA (unstable angina)/NSTEMI (non ST segment elevation myocardial infarction) who have been initially treated with fondaparinux. https://clinicaltrials.gov/ct2/show/NCT00790907

Eligibility Bridge Acute Coronary Syndrome NCT00767507 - Eligibility Criteria

- 28.07.15 - 1 Formular, 2 Itemgruppen, 9 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
The purpose of this study is to demonstrate that patients receiving cangrelor infusion before coronary artery bypass grafting have an acceptable safety profile and can undergo surgery without excessive bleeding peri-operatively. https://clinicaltrials.gov/ct2/show/NCT00767507

Eligibility Vascular Inflammation Acute Coronary Syndrome NCT00552188 - Eligibility Critera

- 28.07.15 - 1 Formular, 2 Itemgruppen, 23 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
The purpose of this study is to determine the effect of VIA-2291 as compared to placebo on vascular inflammation following 24 weeks of dosing. https://www.clinicaltrials.gov/ct2/show/NCT00552188

Eligibility RegistStents Acute Coronary Syndrome NCT01171612 - Eligibility criteria

- 28.07.15 - 1 Formular, 2 Itemgruppen, 12 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
The purpose of this study is to evaluate and monitor perioperative management of patients with coronary stents undergoing noncardiac surgery. https://clinicaltrials.gov/ct2/show/NCT01171612

Eligibility MINT Acute Coronary Syndrome NCT01167582 - Eligibility Criteria

- 28.07.15 - 1 Formular, 2 Itemgruppen, 17 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
The purpose of this study is to evaluate two approaches to red blood cell transfusion in anemic patients with acute coronary syndrome. https://clinicaltrials.gov/ct2/show/NCT01167582

Eligibility RACS Acute Coronary Syndrome NCT00521976 - Eligibility criteria

- 28.07.15 - 1 Formular, 2 Itemgruppen, 7 Datenelemente, 1 Sprache
Itemgruppen: Inclusion Criteria, Exclusion Criteria
The main aim of this trial is to assess the long-term prognostic value of different types of Factor XIIa in an unselected, single center series of 871 chest pain patients admitted to the emergency unit, employing blood samples collected at admission. The second purpose of this study is to assess the incremental prognostic value of B-type natriuretic peptide (BNP) and high-sensitive C-reactive protein (hsCRP). A third purpose of this study is to evaluate the prognostic impact of the Omega-3 Index which is a measure of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) relative to other fatty acids in the erythrocyte membrane.

TIMI Risk Score for STEMI

- 14.04.15 - 1 Formular, 1 Itemgruppe, 8 Datenelemente, 1 Sprache
Itemgruppe: Score Items
The TIMI risk score for STEMI captures the majority of prognostic information offered by a full logistic regression model but is more readily used at the bedside. This risk assessment tool is likely to be clinically useful in the triage and management of fibrinolytic-eligible patients with STEMI. (http://www.ncbi.nlm.nih.gov/pubmed/11044416)

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video